Liver injuries prompt clinical hold on Sanofi BTK drug
One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical […]
One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical […]
The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. While U.S. […]
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the […]
Biogen has licensed rights to a digital therapeutic (DTx) developed by MedRhythms which combines sensors, software, and music to help people with multiple sclerosis tackle […]
Biogen struck a deal that could bring a digital therapeutic to its multiple sclerosis product portfolio. The drugmaker is partnering with startup MedRhythms in the […]
Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen’s oral therapy Vumerity, after NICE recommended the […]
What You Should Know: – XRHealth, the gateway to the healthcare metaverse, announced today that they raised $10M in funding to expand virtual healthcare treatment in the Metaverse. The […]
Novartis has blocked an attempt by Chinese drugmaker HEC Pharma to launch a generic version of its big-selling multiple sclerosis drug Gilenya in the US […]
MSCopilot, a smartphone-based app that is used by patients with multiple sclerosis to gauge how their symptoms are developing, has been shown to correlate closely […]
NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s not good news for patients with the […]
Shots: The companies collaborated to launch a digital companion app i.e., Brisa to treat patients with MS. The app will be offered free of charge […]
By paying $125 million up front for rights to multiple sclerosis drug candidate orelabrutinib, Biogen secures a place among those companies trying to treat the […]
Biogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese biotech InnoCare currently in mid-stage clinical testing. […]
Shots: InnoCare to receive $125M as up front & is eligible to receive ~ $812.5M as development & commercial milestones, following the achievement of definite […]
Chronic diseases are the biggest threat to our global socio-economic development. Lifestyle diseases including heart disease, neuro-degenerative disease, diabetes, and cancer collectively kill almost 50 […]
In an interview with PharmaShots, Dr. Allitia DiBernardo, Global Head of Medical Affairs for Neurology at the Janssen share her views on the availability of […]
NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and […]
Shots: Repertoire and Yale University collaborated to understand the immunological causes of MS by identifying the specificity of various subsets of T cells The focus […]
In an interview with PharmaShots, Monica Mann, Head of Global Medical, Multiple Sclerosis at Biogen shares her views on the Plegridy and how it works […]
Shots: The interim analysis of open-label P- IIIb ENSEMBLE study of Ocrevus (ocrelizumab) showed 85% of patients achieved no evidence of disease activity in early-stage […]
A Helius Medical Technologies medical device that stimulates the brain by sending electrical stimulation to the tongue has received FDA clearance for multiple sclerosis patients. […]
Shots: The approval is based on two clinical studies and a retrospective analysis of RWD. The device is intended to be used by prescription only […]
La industria farmacéutica carece de ensayos clínicos controlados y aleatorios que puedan establecer claramente los beneficios y los riesgos de su uso.
La industria farmacéutica carece de ensayos clínicos controlados y aleatorios que puedan establecer claramente los beneficios y los riesgos de su uso.
The industry lacks randomized controlled clinical trials that can clearly establish benefits and risks.
The industry lacks randomized controlled clinical trials that can clearly establish benefits and risks.
The European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company illegally delayed launches and use of generic […]
COVID-19 has increased demands on informal carers and severely increased demands on their mental, physical and financial wellbeing, according to a global study. Embracing Carers […]
Shots: The multicenter survey involves assessing Kesimpta Sensoready autoinjector pen in 80 MS patients and 50 MS nurses, with RMS who received a disease modifying […]
Scotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide following a draft rejection in England by […]
Novartis’ multiple sclerosis drug has been given the green light by the European Medicines Agency’s CHMP scientific committee, paving the way for a likely approval […]
Dr. Nandor Pinter, Director of Neuroimaging Research, DENT Institute Dr. Murray Gillies, General Manager of Digital Cognitive Dx Venture, Philips The field of neurology is […]
NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing multiple sclerosis in first draft guidance. The […]
Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseases including Parkinson’s disease. Over […]
Shots: The approval is based on ENSEMBLE PLUS study, which demonstrated similar frequency and severity of IRRs for 2hrs. Ocrevus infusion time vs conventional 3.5hrs […]
Janette Curlis is a Multiple Sclerosis Nurse Advisor (MSNA) at Biogen, helping to support the company’s Multiple Sclerosis (MS) field teams and developing patient and […]
The years of healthy life lost due to our consumption of trans fats are comparable to the impact of conditions like meningitis, cervical cancer, and […]
Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a […]
UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance. The […]
Cleveland Clinic’s top clinicians and researchers present the top 10 medical innovations transforming medical advancements and new awards to recognize healthcare innovation. The list of […]
It’s mission accomplished for Novartis after the FDA approved ofatumumab for multiple sclerosis, completing a project where the former cancer drug has been repurposed. The […]
Shots: The approval is based on P-III ASCLEPIOS I & II studies assessing Kesimpta (20mg, monthly, SC) vs teriflunomide (14mg, qd) in 1,882 patients aged […]
Shares in Teva were down sharply this week after the US Department of Justice filed a complaint that the company paid illegal kickbacks to patient […]
The French drugmaker will take full control of SAR442168, a BTK inhibitor developed for multiple sclerosis that it in-licensed from the California biotech company in […]
Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to its pipeline. The French pharma said it […]
Shots: The real-world evidence partnership will allow the Roche to access PicnicHealth’s set of de-identified patient records to gain insights on certain diseases and treatments […]
The companies will use a combination of more than seven years of medical record data with five years of prospective data on 5,000 MS patients, […]
Cutting two teaspoons of salt’s worth of sodium from one’s daily diet can significantly improve lung function in asthmatics In the 1960s and 1970s, a […]
Copyright © 2024 | WordPress Theme by MH Themes